Sage Journals: Discover world-class research

Abstract

Objective

To evaluate the safety and efficacy of rituximab in patients suffering from rhupus unresponsive to therapy with non-biological disease-modifying anti-rheumatic drugs (DMARDs).

Methods

Six patients fulfilling criteria for both rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) and with a DAS28 score >5.1 were enrolled to receive two fortnightly 1000 mg rituximab doses at baseline and after 28 weeks. All patients underwent clinical, laboratory, and power- Doppler (PD) ultrasonographic (US) assessment at baseline and after 14, 28 and 56 weeks.

Results

A sustained improvement in DAS28, SLEDAI, HAQ, laboratory markers and ultrasound indices together with a significant reduction in the daily dose of prednisone were observed throughout follow-up.

Conclusion

Rituximab may be a safe and effective therapeutic option in refractory rhupus patients.

Keywords

systemic lupus erythematosus rheumatoid arthritis rituximab musculoskeletal ultrasound rhupus

Get full access to this article

View all access options for this article.

References

Ball

Bell

. Lupus arthritis–do we have a clinically useful classification? Rheumatology (Oxford) 2012; 51: 771–9.

Amezcua-Guerra

. Overlap between systemic lupus erythematosus and rheumatoid arthritis: is it real or just an illusion? J Rheumatol 2009; 36: 4–6.

Keystone

Emery

Peterfy

. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2009; 68: 216–21.

Tak

Rigby

Rubbert-Roth

. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011; 70: 39–46.

Aringer

Smolen

. Therapeutic blockade of TNF in patients with SLE – promising or crazy? Autoimmun Rev 2012; 11: 321–5.

Aringer

Graninger

Steiner

. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004; 50: 3161–9.

Grunke

Antoni

Kavanaugh

. Standardization of joint examination technique leads to a significant decrease in variability among different examiners. J Rheumatol 2010; 37: 860–4.

Wakefield

Balint

Szkudlarek

. Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol 2005; 32: 2485–7.

Ramos-Casal

Soto

Cuadrado

. Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases. Lupus 2009; 18: 767–76.

10.

Terrier

Amoura

Ravaud

. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010; 62: 2458–66.

11.

Wright

Filippucci

Grassi

Grey

Bell

. Hand arthritis in systemic lupus erythematosus: an ultrasound pictorial essay. Lupus 2006; 15: 501–6.

12.

Gabba A, Piga M, Vacca A, et al. Joint and tendon involvement in Systemic Lupus Erythematosus. An ultrasound study of hands and wrists in 108 patients. Rheumatology (Oxford) 2012; 51: 2278–85.

13.

Piga

Gabba

Vacca

. Multiple septic bursitis and spontaneous Achilles tendon tear in systemic lupus erythematosus. J Rheumatol 2010; 37: 2438–40.

14.

Murphy

Isenberg

. Connective tissue diseases: SLE-associated arthropathy: Truly a benign entity? Nat Rev Rheumatol 2012; 8: 695–6.

15.

Naredo

Möller

Cruz

Carmona

Garrido

. Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Arthritis Rheum 2008; 58: 2248–56.

Rituximab treatment for ‘rhupus syndrome’: clinical and power-Doppler ultrasonographic monitoring of response. A longitudinal pilot study